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Key Points
• PT-Cy–based Haplo-
HCT resulted in less
chronic GVHD com-
pared to matched sib-
ling transplantation in
patients with AML in
CR1.
• Survival, relapse, non-
relapse mortality, and
acute GVHD rates
were not different be-
tween the 2
approaches.
HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using
posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However,
a matched sibling donor (MSD) is still considered the optimal donor. Using the Center for
International Blood and Marrow Transplant Research database, we compared outcomes
after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) in first complete
remission (CR1). Data from 1205 adult CR1 AML patients (2008-2015) were analyzed. A total
of 336 patients underwent PT-Cy–based Haplo-HCT and 869 underwent MSD using
calcineurin inhibitor–based graft-versus-host disease (GVHD) prophylaxis. The Haplo-HCT
group included more reduced-intensity conditioning (65% vs 30%) and bone marrow grafts
(62% vs 7%), consistent with current practice. Inmultivariable analysis, Haplo-HCT andMSD
groups were not different with regard to overall survival (P 5 .15), leukemia-free survival
(P 5 .50), nonrelapse mortality (P 5 .16), relapse (P 5 .90), or grade II-IV acute GVHD (P 5
.98). However, the Haplo-HCT group had a significantly lower rate of chronic GVHD (hazard
ratio, 0.38; 95% confidence interval, 0.30-0.48; P , .001). Results of subgroup analyses by
conditioning intensity and graft source suggested that the reduced incidence of chronic
GVHD in Haplo-HCT is not limited to a specific graft source or conditioning intensity. Center
effect and minimal residual disease–donor type interaction were not predictors of outcome.
Our results indicate a lower rate of chronic GVHD after PT-Cy–based Haplo-HCT vs MSD
using calcineurin inhibitor–based GVHD prophylaxis, but similar other outcomes, in
patients with AML in CR1. Haplo-HCT is a viable alternative to MSD in these patients.
Introduction
Allogeneic hematopoietic cell transplantation (HCT) is a potentially
curative treatment modality for patients with acute myeloid leukemia
(AML). Although an HLA-matched sibling donor (MSD) is consid-
ered the optimal donor,1,2 alternative donors have permitted safe
and effective HCT for patients lacking an MSD. HLA-haploidentical
hematopoietic cell transplantation (Haplo-HCT) is one such
approach. Haplo-HCT is performed most commonly using post-
transplantation cyclophosphamide (PT-Cy) as the backbone for
graft-versus-host disease (GVHD) prophylaxis.3,4
Several studies have compared the outcomes of Haplo-HCT vs
umbilical cord blood5-7 and matched unrelated donor (MUD)
HCT.8-13 In addition, 4 large retrospective studies compared
MSD vs Haplo-HCT. In 1 study comparing reduced-intensity
conditioning (RIC) MSD vs PT-Cy–based Haplo-HCT in patients
with lymphoma, outcomes were similar between the 2 groups, with
the exception that a lower incidence of chronic GVHD was evident
in the Haplo-HCT cohort.14 In another study comparing PT-
Cy–based Haplo-HCT with MSD and MUD for patients with
Hodgkin lymphoma, Haplo-HCT was associated with less relapse
and chronic GVHD compared with MSD.11 A third study compared
Haplo-HCT and MSD in patients with intermediate- or poor-risk
AML in first complete remission (CR1). Among high-risk patients, no
outcome differences were observed between the groups, with the
exception that there was more grade II-IV acute GVHD and a trend
for less relapse after Haplo-HCT.15 Among intermediate-risk
patients, nonrelapse mortality (NRM), leukemia-free survival (LFS),
and overall survival (OS) were worse after Haplo-HCT. Importantly,
26% of Haplo-HCT recipients in this study did not receive PT-Cy.
Finally, in a study comparing MSD and PT-Cy–based Haplo-HCT in
patients with AML or acute lymphoblastic leukemia,16 the incidence
of chronic GVHD was lower after Haplo-HCT. Other outcomes
were similar between the groups for patients younger than 55 years.
In contrast, in patients aged 55 years or older, MSD yielded lower
rates for graft failure, NRM, and overall mortality compared with
Haplo-HCT from an offspring.
A common theme among these studies is a reduced incidence of
chronic GVHD after PT-Cy–based Haplo-HCT. However, these
studies have important differences in their patient-, disease-, and
transplant-related characteristics, highlighting the need to analyze
more homogenous cohorts. Using such cohorts would minimize
confounding and increase the likelihood of detecting donor
type–specific differences in outcomes. Therefore, we designed
the present study to compare the outcomes of MSD with PT-
Cy–based Haplo-HCT using a relatively homogenous group of
patients with AML in CR1.
Methods
Data sources
The Center for International Blood and Marrow Transplant Re-
search (CIBMTR) includes data from a voluntary working group of
.450 transplant centers worldwide that contributes detailed data
on allogeneic and autologous HCT. Participating centers are
required to report all transplants consecutively; compliance is
monitored by on-site audits, and patients are followed longitudinally.
Computerized checks for discrepancies, physicians’ review of
submitted data, and on-site audits of participating centers ensure
data quality. Studies conducted by the CIBMTR are performed in
compliance with all applicable federal regulations pertaining to
the protection of human research participants. Protected health
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information used in the performance of such research is collected
and maintained in CIBMTR’s capacity as a Public Health Authority
under the HIPAA Security Rule. The CIBMTR collects data at 2
levels: the transplant essential data (TED) level and the compre-
hensive report form (CRF) level. The TED-level data are an
internationally accepted standard data set that contains a limited
number of key variables for all consecutive transplant recipients.
Details on CRF- and TED-level data collection have been published
previously and are described in detail elsewhere.17 TED- and CRF-
level data are collected pretransplant, 100 days and 6 months
posttransplant, annually until year 6 posttransplant, and biannually
thereafter until death.
Patients
We included all adult patients (age$18 years) with AML who were
in CR1 at the time of their first allogeneic HCT (between 2008 and
2015) using an MSD or a haploidentical related donor (mismatched
for$2 HLA loci among HLA-A, HLA-B, HLA-C, and HLA-DRB1). In
the Haplo-HCT group, only cases receiving PT-Cy–based GVHD
prophylaxis (with or without a calcineurin inhibitor [CNI] and
mycophenolate mofetil) were included, whereas in the MSD group,
GVHD prophylaxis was limited to CNI-based approaches. Patients
receiving ex vivo (T-cell–depleted or CD34-selected grafts) or
in vivo (eg, anti-thymocyte immunoglobulin) graft manipulation were
excluded. Both peripheral blood and bone marrow as a graft source
and myeloablative conditioning (MAC) and RIC regimens were
included. The Institutional Review Board of the National Marrow
Donor Program approved this study.
End points and definitions
The primary end point was OS. Secondary end points were
hematopoietic recovery, relapse, LFS, NRM, and acute and chronic
GVHD. OS was defined as the time from HCT to death from any
cause. LFS was defined as survival with no evidence of relapse or
progression. Relapse was defined as the reappearance of $5%
blasts on morphological evaluation in bone marrow or an
extramedullary site. NRM was defined as death without evidence
of relapse or progression. Acute and chronic GVHD were defined
according to standard criteria.18 Neutrophil engraftment was
defined as achieving an absolute neutrophil count $ 0.53 109/L
for 3 consecutive days, and platelet engraftment was defined as
a platelet count $203 109/L for 7 days unsupported by
transfusion.
Cytogenetic risk was defined according to SWOG classification.19
Minimal residual disease (MRD) information before HCT was not
collected consistently or reported to the CIBMTR during the period
of this study. However, given its key importance in HCT out-
comes,20 we used all relevant reported variables to generate an
estimate for MRD before HCT (supplemental Table 1). We
classified a patient as MRD positive in the following scenarios
pre-HCT: (1) answer was “no” to questions on cytogenetic,
molecular, or flow cytometry-based remission; (2) answer was
“yes” to the question on disease detectability in the blood or bone
marrow by flow cytometry; or (3) answer was “yes” to the presence
of molecular markers, such as CEBPA, FLT3 D835, FLT3-ITD,
IDH1, IDH2, KIT, or NPM1 mutation. We classified a patient as
MRD negative if they were not classified as MRD positive and (1)
answer was “no” to the question on disease detectability in the
blood or bone marrow by flow cytometry or (2) answer was “yes” to
questions on cytogenetic, molecular, or flow cytometry-based
remission. HCT comorbidity index (HCT-CI) was defined according
to standard criteria.21
Statistical methods
Patient- and transplant-related variables were compared using the
x2 test for categorical variables and the Mann-Whitney U test for
continuous variables. Kaplan-Meier curves were used to estimate
the probability of OS and LFS. Cumulative incidence was used to
estimate the probability of NRM, GVHD, and relapse. For GVHD
and relapse, NRM was treated as a competing risk. For NRM,
relapse was treated as a competing risk. For LFS and OS, patients
were censored at the time of last follow-up.
Univariate analysis was performed for the main effect (donor type) in
relation to outcomes. In multivariable Cox proportional-hazards
models, donor type (main effect) was forced in, and a backward
stepwise model selection approach using the Akaike information
criterion was used to identify a priori selected potential predictors of
outcomes (supplemental Table 2). Covariates significant at a 5%
level were kept in the final model. The assumption of proportional
hazards for each factor in the Cox model was tested by adding time-
dependent covariates. Potential interactions between main effect
and significant covariates were tested. Transplantation center effect
was tested using the frailty model.22 Adjusted probabilities of LFS
and OS, as well as adjusted cumulative incidence functions of NRM
and relapse, were calculated using multivariable models, stratified
on the main effect and weighted by the pooled sample proportion
value for each prognostic factor.
We hypothesized that OS following PT-Cy–based Haplo-HCT is
not significantly different from MSD using CNI-based GVHD
prophylaxis in AML patients in CR1. Assuming that there is
a $10% difference between the groups in 3-year OS, using a 2-
sided test (allowing for the difference to be in either direction) at 5%
significance level, and with the available sample size that we
identified in the CIBMTR database, we had 86% power to detect
this difference. All analyses were done using the statistical package
SAS version 9.3 (SAS Institute, Cary, NC).
Results
Data from 1205 patients (Haplo-HCT, n 5 336; MSD, n 5 869)
were analyzed. Patient, disease, and transplant characteristics are
shown in Table 1. Patients were older and donors were younger in
the Haplo-HCT group; 55% vs 38% of Haplo-HCT vs MSD
recipients and 11% vs 35% of Haplo-HCT vs MSD recipients were
$55 years of age (P , .001 for both comparisons). There were
more African American patients in the Haplo-HCT group compared
with the MSD group (21% vs 5%, P, .001). The Haplo-HCT group
included more RIC (65% vs 30%, P , .001) and bone marrow
grafts (62% vs 7%, P , .001), consistent with current practice. In
addition, a smaller proportion of Haplo-HCT recipients were white
(68% vs 84%, P , .001) and a smaller proportion underwent HCT
within 6 months of diagnosis compared with the MSD group (69%
vs 83%, P , .001). Intermediate-risk cytogenetics was more
common in the MSD group (65% vs 50%, P, .001). As expected,
a smaller proportion of Haplo-HCT vs MSD transplants were
performed before 2011 (11% vs 49%, P , .001).
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Table 1. Patients, disease, and transplant characteristics
Variable Haplo (n 5 336) MSD (n 5 869) P
Patient age, y ,.001
18-54 152 (45) 542 (62)
$55 184 (55) 327 (38)
Median (range) 57 (18-74) 52 (18-71)
Donor age, y ,.001
18-54 212 (63) 560 (64)
$55 37 (11) 306 (35)
Missing 87 (26) 3 (,1)
Median (range) 39 (16-68) 51 (18-73)
Sex .42
Male 183 (54) 451 (52)
Female 153 (46) 418 (48)
Race ,.001
White 229 (68) 727 (84)
African American 69 (21) 46 (5)
Others 20 (6) 70 (8)
Missing 18 (5) 26 (3)
HCT-CI .20
0 99 (29) 254 (29)
1 53 (16) 136 (16)
2 43 (13) 124 (14)
$3 133 (40) 309 (36)
Missing 8 (2) 46 (5)
Karnofsky performance status .78
,90 112 (33) 308 (35)
$90 208 (62) 551 (64)
Missing 16 (5) 10 (1)
Time from diagnosis to HCT, mo ,.001
,6 231 (69) 721 (83)
6-12 89 (26) 131 (15)
.12 16 (5) 17 (2)
Median (range) 5 (2-36) 4 (1-18)
Type of AML .05
De novo 244 (73) 662 (76)
Transformed from MDS/MPN 70 (21) 133 (15)
Therapy related 22 (6) 74 (9)
Donor/recipient cytomegalovirus serostatus .26
1/1 139 (41) 328 (38)
1/2 29 (9) 98 (11)
2/1 91 (27) 223 (26)
2/2 75 (22) 204 (23)
Missing 2 (,1) 16 (2)
Donor/recipient sex .47
Male-male 114 (34) 256 (29)
Male-female 88 (26) 231 (26)
Female-male 69 (21) 195 (23)
Unless otherwise noted, all data are n (%).
Haplo, haploidentical; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm.
*All Haplo-HCT patients received PT-Cy, whereas all MSD patients received a CNI.
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Univariate analysis
Acute and chronic GVHD. In univariate analysis (Table 2),
the Haplo-HCT group had similar rates of grade II-IV acute GVHD
(32%; 95% confidence interval [95% CI], 27-37 vs 30%, 95% CI,
27-33; P 5 .64) and grade III-IV acute GVHD (10%; 95% CI, 7-14
vs 12%; 95% CI, 10-14; P 5 .54) at 6 months but lower rates of
chronic GVHD (26%, 95% CI, 21-31 vs 56%; 95% CI, 53-60 at
3 years; P , .001) and extensive chronic GVHD (16%; 95% CI,
12-20 vs 47%; 95% CI, 44-50 at 3 years; P , .001).
Mortality and relapse. The Haplo-HCT group had a lower
OS (48%; 95% CI, 42-54 vs 55%; 95% CI, 52-59 at 3 years;
P5 .03) and a trend for higher NRM (19%; 95%CI, 15-24 vs 14%;
95%CI, 12-17 at 3 years; P5 .06) but similar relapse (P5 .90) and
LFS (P 5 .11). Center effect (tested for OS) was not significant
(P 5 .08).
Engraftment. Neutrophil and platelet engraftment rates were
lower in the Haplo-HCT group (92%; 95% CI, 89-95 vs 99%; 95%
CI, 98-99 for neutrophils at 1 month; P , .001 and 89%; 95% CI,
85-92 vs 97%; 95% CI, 96-98 for platelets at 100 days, P, .001).
Multivariable analysis
OS and LFS. Haplo-HCT and MSD groups were not differ-
ent with regard to OS (hazard ratio [HR], 1.15; 95% CI, 0.95-1.38;
P 5 .15) (Figure 1). Significant predictors of worse OS included
older age (P 5 .02), worse performance status (Karnofsky per-
formance status , 90 vs 901, P 5 .01), MRD positivity before
HCT (P 5 .005), worse cytogenetic risk (P , .001), secondary
AML (P , .001), and recipient male sex (P 5 .03) (Table 3).
Haplo-HCT and MSD groups were not different with regard to LFS
(HR, 1.06; 95% CI, 0.89-1.27; P 5 .50) (Figure 1). Significant
predictors of worse LFS included older age (P 5 .04), MRD
Table 1. (continued)
Variable Haplo (n 5 336) MSD (n 5 869) P
Female-female 65 (19) 187 (22)
Cytogenetics ,.001
Favorable 12 (4) 26 (3)
Intermediate 170 (50) 560 (64)
Poor: monosomal karyotype 33 (10) 76 (9)
Poor: other 70 (21) 174 (20)
Not tested or missing 51 (15) 33 (4)
MRD prior to HCT .10
Negative 250 (74) 598 (62)
Positive 66 (20) 192 (29)
Missing 20 (6) 79 (9)
Conditioning intensity ,.001
MAC with TBI 34 (10) 216 (24)
MAC without TBI 83 (25) 396 (45)
RIC/nonmyeloablative 219 (65) 250 (30)
Missing 0 7 (,1)
Graft source ,.001
Bone marrow 208 (62) 56 (7)
Peripheral blood 128 (38) 813 (93)
GVHD prophylaxis* ,.001
CNI 1 methotrexate 6 others 3 (,1) 622 (70)
CNI 1 mycophenolate mofetil 6 others 322 (96) 154 (19)
Others 9 (3) 88 (11)
Missing 2 (,1) 5 (,1)
Year of HCT ,.001
2008-2010 36 (11) 424 (49)
2011-2015 300 (89) 445 (51)
Median follow-up of survivors (range), mo 35 (3-97) 60 (3-119)
Unless otherwise noted, all data are n (%).
Haplo, haploidentical; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm.
*All Haplo-HCT patients received PT-Cy, whereas all MSD patients received a CNI.
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positivity before HCT (P, .001), worse cytogenetic risk (P, .001),
and secondary AML (P 5 .008) (Table 3).
Relapse and NRM. Haplo-HCT and MSD groups were not
different with regard to NRM (HR, 1.26; 95% CI, 0.92-1.74; P 5 .16)
(Figure 1). Significant predictors of higher NRM included older age
(P , .001), recipient male sex (P 5 .01), and worse comorbidity
score (P 5 .005). MAC with total body irradiation (TBI) was
predictive of higher NRM (P5 .04 vs MAC without TBI, P5 .008 vs
RIC). Recipient cytomegalovirus seronegativity was predictive of
less NRM (P 5 .01 if donor seropositive, P 5 .03 if donor
seronegative) (Table 3).
Haplo-HCT and MSD groups were not different with regard to
relapse (HR, 0.88; 95% CI, 0.70-1.10; P 5 .27) (Figure 1).
Predictors of relapse were MRD positivity before HCT (P , .001),
worse cytogenetic risk (P , .001), and RIC (P 5 .008) (Table 3).
Acute and chronic GVHD. Haplo-HCT and MSD groups
were not different with regard to grade II-IV acute GVHD (HR, 1.01;
95% CI, 0.80-1.26; P 5 .98) (Figure 1). No factor other than the
main effect (donor type) remained in the final model (Table 3).
Similarly, the groups were not different with regard to grade III-IV
acute GVHD (HR, 0.81; 95% CI, 0.55-1.21; P 5 .30).
However, the Haplo-HCT group had a lower rate of chronic GVHD
(HR, 0.38; 95% CI, 0.30-0.48; P , .001) (Figure 1). Other factors
significantly associated with an increased risk for chronic GVHD
were using a female donor (P 5 .007 for male patient and P 5 .02
for female patient vs a male-to-male transplant) and MAC without
TBI (compared with MAC with TBI, P 5 .05) (Table 3).
The interaction between MRD positivity and donor type did not
influence any of the outcomes.
Subgroup analysis
Next, we performed multivariable subgroup analyses to evaluate
whether the association between Haplo-HCT and less chronic
GVHD is limited to MAC vs RIC or peripheral blood vs bone marrow.
When the analysis was limited to the MAC subgroup, Haplo-HCT
was associated with a lower risk for chronic GVHD (HR, 0.44; 95%
CI, 0.31-0.61; P , .001) compared with MSD. A similar result was
obtained with analysis limited to RIC cases (Haplo-HCT vs MSD:
HR, 0.34; 95% CI, 0.25-0.48; P , .001). When the analysis was
limited to peripheral blood cases, Haplo-HCT was associated with
a lower risk for chronic GVHD compared with MSD (HR, 0.68; 95%
CI, 0.50-0.91; P 5 .009). The association was even stronger when
the analysis was limited to bone marrow grafts (HR, 0.22; 95% CI,
0.15-0.31; P , .001). These results indicate that the association
between Haplo-HCT and less chronic GVHD is not limited to
a specific conditioning intensity or graft source.
Causes of death
Overall, 170 deaths occurred in the Haplo-HCT group, and 425
occurred in the MSD group. The 3 most common causes of death
were similar between the groups: relapse (58% vs 60%, re-
spectively), GVHD (1% acute and 0.6% chronic vs 4% acute and
6% chronic, respectively), and infection (8% vs 10%, respectively).
Discussion
Our results from this large CIBMTR analysis of AML patients
transplanted in CR1 indicate similar outcomes after current
standard practices of PT-Cy–based Haplo-HCT vs MSD HCT,
with the exception of less chronic GVHD after Haplo-HCT. The
unique features of our study were its focus on patients with AML in
CR1 and inclusion of MRD information. Because MRD was not
uniformly tested or reported by CIBMTR centers, we created
a logical definition of MRD using the available data. The balance
between the groups using our MRD definition was important in the
analysis of outcomes. Our subgroup analyses suggested that the
reduced incidence of chronic GVHD in Haplo-HCT was not limited
to a specific graft source or conditioning intensity.
The reduction in the incidence of chronic GVHD in our study was
not associated with improved survival. Although prospective studies
of Haplo-HCT vs MSD have not been performed, our finding is
consistent with large randomized studies in other settings, such as
matched donor transplant using peripheral blood vs bone marrow
as a graft source.23 Late infections and secondary malignancies are
among the causes of NRM that could offset a potential survival
benefit of less chronic GVHD. However, data on these factors were
not available in the present study. Similarly, reduced rates of chronic
GVHD in the Haplo-HCT group in our study were not associated
with increased relapse. Our analysis was strengthened by disease
uniformity (AML in CR1) and balanced MRD status between the
groups, 2 key factors in the analysis of relapse. A previous study
Table 2. Univariate analysis of outcomes
Outcomes Haploidentical MSD P
Neutrophil engraftment at 1 mo 92 (89-95) 99 (98-99) ,.001
Platelet engraftment at 100 d 89 (85-92) 97 (96-98) ,.001
Grade II-IV acute GVHD .98
100 d 31 (26-36) 26 (23-29) .09
6 mo 32 (27-37) 30 (27-33) .64
Grade III-IV acute GVHD .28
100 d 10 (7-14) 10 (8-12) .94
6 mo 10 (7-14) 12 (10-14) .54
Chronic GVHD ,.001
1 y 22 (18-27) 48 (45-52) ,.001
3 y 26 (21-31) 56 (53-60) ,.001
Extensive chronic GVHD ,.001
1 y 15 (11-19) 41 (38-44) ,.001
3 y 16 (12-20) 47 (44-50) ,.001
Relapse .88
1 y 30 (25-35) 30 (27-34) .92
3 y 38 (33-44) 38 (34-41) .90
NRM .06
1 y 13 (10-17) 10 (8-12) .12
3 y 19 (15-24) 14 (12-17) .06
LFS .23
1 y 56 (51-62) 59 (56-63) .34
3 y 43 (37-48) 48 (45-51) .11
OS .03
1 y 67 (62-72) 70 (67-73) .23
3 y 48 (42-54) 55 (52-59) .03
All data are % (95% CI).
25 JUNE 2019 x VOLUME 3, NUMBER 12 HAPLOIDENTICAL VS MATCHED SIBLING HCT FOR CR1 AML 1831
.For personal use onlyon July 17, 2019. by guest  www.bloodadvances.orgFrom 
comparing Haplo-HCT and MSD in patients with acute leukemia
showed consistent results.16 In contrast, a recent study comparing
the outcomes of Haplo-HCT and MSD in patients with relapsed/
refractory AML showed worse outcomes (LFS, OS, NRM,
infections) after Haplo-HCT.24
Chronic GVHD and its complications are the primary determinants
of long-term quality of life after allogeneic HCT,25-27 although this
relationship has not been studied after Haplo-HCT. Future research
should address whether reduced chronic GVHD after Haplo-HCT
results in better quality of life.
In a large study comparing PT-Cy–based Haplo-HCT with MUD in
patients with AML, the incidence of acute and chronic GVHD was
lower after Haplo-HCT, with no survival difference.9 Our cohorts
were not different with regard to the incidence of acute GVHD, likely
because of less acute GVHD in MSD compared with MUD.
However, chronic GVHD results were consistent between the 2
studies, with Haplo-HCT yielding the best results. Considering our
negative subgroup analyses for graft source and conditioning
intensity, the lower incidence of chronic GVHD after Haplo-HCT is
likely due to PT-Cy. This finding may explain negative findings for
chronic GVHD in a previous large study of Haplo-HCT vs MSD in
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Figure 1. Outcomes after Haplo-HCT vs MSD in patients with AML in CR1. Adjusted curves for OS (A), LFS (B), relapse (C), NRM (D), grade II-IV acute GVHD (E),
and chronic GVHD (F).
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Table 3. Multivariable analysis of outcomes













,90 1.23 (1.04-1.45) .01
Missing 0.80 (0.44-1.47) .47
Cytogenetics ,.001
Favorable Reference
Intermediate 1.29 (0.74-2.25) .38
Poor: monosomal karyotype 2.51 (1.39-4.54) .002
Poor: other 1.89 (1.07-3.34) .03
Missing 1.78 (0.96-3.31) .07
MRD at HCT .009
Negative Reference
Positive 1.32 (1.09-1.61) .005
















1 1.36 (0.86-2.17) .19
2 1.02 (0.61-1.73) .93
31 1.88 (1.31-2.71) ,.001
Missing 1.42 (0.67-3.05) .36
Conditioning .06
MAC-TBI Reference
MAC without TBI 0.67 (0.47-0.98) .04
RIC 0.57 (0.38-0.86) .008
Missing 0.56 (0.08-4.14) .57
Table 3. (continued)
Covariates HR (95% CI) P
D/R CMV status ,.001
1/1 Reference
1/2 0.46 (0.25-0.84) .01
2/1 0.94 (0.67-1.31) .70
2/2 0.67 (0.46-0.97) .03










Intermediate 1.26 (0.76-2.09) .37
Poor: monosomal karyotype 2.37 (1.38-4.06) .002
Poor: other 1.78 (1.06-2.99) .03
Missing 1.62 (0.92-2.87) .09
MRD at HCT ,.001
Negative Reference
Positive 1.41 (1.18-1.70) ,.001










Intermediate 1.26 (0.69-2.32) .45
Poor: monosomal karyotype 2.48 (1.30-4.72) .006
Poor: other 2.01 (1.08-3.74) .03
Missing 1.76 (0.88-3.50) .11
MRD at HCT .003
Negative Reference
Positive 1.45 (1.17-1.80) ,.001
Missing 1.19 (0.84-1.67) .33
Conditioning .004
MAC-TBI Reference
MAC without TBI 1.01 (0.78-1.30) .95
RIC 1.43 (1.10-1.85) .008
Missing 0.35 (0.05-2.50) .29
aGVHD II-IV
Main effect .95
aGVHD, acute GVHD; CMV, cytomegalovirus; D/R, donor/recipient; F, female; M, male;
TBI, total body irradiation.
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patients with intermediate- or poor-risk AML in CR1, because more
than 25% of Haplo-HCT patients in that study did not receive PT-
Cy.15 Most of our MSD recipients received peripheral blood stem
cells, and nearly half developed chronic GVHD at 1 year. The
efficacy of PT-Cy in reducing chronic GVHD rates in this setting has
been demonstrated in a previous work.28
The associations between donor type and outcome in our study did
not depend on MRD status before HCT. To our knowledge, only 1
previous study found differential outcomes between donor types
depending on MRD status.29 In that study, patients with AML or
myelodysplastic syndrome received a myeloablative cord blood or
MUD transplant. The use of cord blood resulted in less relapse and
higher OS compared with the use of an unrelated donor if patients
were MRD positive at the time of HCT. This donor-specific
association was not present in MRD-negative patients. Although
prospective trials should use current and novel high-sensitivity
techniques for MRD assessment, the method developed in this
study may be tested in, and applied to, future CIBMTR studies of the
pre-MRD era.
Donor age and relationship to the recipient in Haplo-HCT outcomes
have been a subject of recent investigation. McCurdy et al showed
that, among Haplo-HCT recipients, patient age (18-54 vs 55-78
years) negated the effect of donor age and relationship on
survival.30 Robinson et al compared the outcomes of MSD vs
Haplo-HCT in patients with acute leukemia. In their study, patients
aged 18 to 54 years experienced lower rates of chronic GVHD if
transplanted from a haploidentical sibling than from an MSD.16
Similarly, older patients had lower rates of chronic GVHD if
transplanted from a haploidentical child than from an MSD.
However, in this older group of patients (55-76 years), NRM and
OS were worse after HCT from haploidentical offspring compared
with an MSD. Although our study was not designed to address
donor relationship in different patient age groups, the results by
McCurdy et al and Robinson et al help to interpret our findings.
Chronic GVHD results seem to be generalizable to different donor
relationships and patient age groups, but the lack of a difference in
NRM and OS between the groups in our study may be subgroup
specific based on patient age and donor relationship.
Our finding of reduced chronic GVHD after Haplo-HCT compared
with an MSD is consistent with previous studies, although specifics
of transplant and patient populations (2 studies in lymphoma and 1
in acute leukemia) varied among studies.11,14,16 Limitations of our
study include its retrospective design, the relatively small number of
centers from which Haplo-HCT cases were reported, small number
of MSD HCTs using bone marrow as a graft source (limiting
subgroup analysis), and lack of chronic GVHD grading and MRD
assessment according to the current standards. Nonetheless, the
available data indicate that PT-Cy–based Haplo-HCT using bone
marrow results in less chronic GVHD vs an MSD using peripheral
blood and CNI-based GVHD prophylaxis. In this study, we did not
consider viral reactivations and hemorrhagic cystitis, which could
differ between the 2 groups.
In conclusion, a haploidentical relative is a viable alternative to an
MSD in AML patients in CR1. The longer interval between diagnosis
and transplant in our Haplo-HCT recipients suggests that, in some
cases, centers might have spent time looking for unrelated donors
before turning to haploidentical donors. Our results can help to
prevent this delay in choosing a suitable donor. Choosing
a haploidentical donor over a matched sibling may be necessary
when stem cell collection from a matched sibling is considered risky
because of comorbidities, and our results provide support for this
approach. In addition, more than one fifth of our Haplo-HCT patients
were African American, supporting the feasibility of using this donor
type in ethnic minorities. Finally, a future study comparing Haplo-
HCT with MSD, using the same graft source and PT-Cy–based
GVHD prophylaxis, would be mechanistically informative about
whether PT-Cy negates the effect of HLA disparity on outcomes.
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